ImpactOS
See an example

Eli Lilly and Company

Companies and groups · United States

In these lists: Medicines

Declared lobbying cost
€900,000 – €999,999 Financial year 01/2025-12/2025
Commission meetings
17
Full-time staff on EU lobbying
1.9
European Parliament access passes
4
Registered since
2 Apr 2010
Public records onlyWhat this means

Every profile, record and figure comes from documents published by EU institutions, national authorities, courts, ethics bodies, the EU Transparency Register or established news outlets. We use no leaks, private data or anonymous tips. AI helps us gather and cross-check sources but never decides anyone's guilt: each record keeps its exact legal status and links to its source, so you can check it yourself

Registering is a legal transparency duty, not a sign of wrongdoing. Budgets and meetings show access, not influence on any particular decision. Register figures as declared on 30 Jun 2026

Fields of interest

Budget, Business and industry, Climate action, Competition, Customs, Digital economy and society, Economy, finance and the euro, Education and training, Employment and social affairs, Energy, Environment, External relations, Food safety, Foreign affairs and security policy, Humanitarian aid and civil protection, Institutional affairs, Public health, Research and innovation, Single market, Taxation, Trade

Medicines and food topics they name

EU medicines law, Critical medicines, Orphan and paediatric medicine incentives, Health technology assessment, Antibiotics and antimicrobials

EU laws and policies they declare following2
  • Revision of pharmaceutical legislation, Intellectual Property Rights and incentives – including Orphan Medicinal products, Paediatric medicines and Anti-Microbial Resistance (AMR), Free Trade Agreeme…
  • Other policy areas of interest include Innovation, Research and Development, Public-Private Partnerships, Mergers and acquisitions, Life sciences, Biopharmaceuticals, Manufacturing including Active P…

Meetings with the Commission

Meetings with Commissioners or their Cabinets since 1 December 2024, as the Commission publishes them

  1. With the Commissioner

    Olivér Várhelyi

    Life Sciences Roundtable

    Published record
  2. With the Commissioner

    Olivér Várhelyi

    EU initiatives in the field of the pharmaceutical sector

    Published record
  3. With the Commissioner

    Olivér Várhelyi

    Challenges and priorities for health and life sciences

    Published record
  4. With the Cabinet

    Olivér Várhelyi

    EU initiatives in the field of the pharmaceutical sector

    Published record
  5. With the Cabinet

    Olivér Várhelyi

    Challenges and priorities for health and life sciences

    Published record
  6. With the Cabinet

    Maroš Šefčovič

    Latest developments in EU-US relations

    Published record
  7. With the Commissioner

    Olivér Várhelyi

    Competitiveness of the pharma industry

    Published record
  8. With the Cabinet

    Olivér Várhelyi

    Competitiveness of the pharma industry

    Published record
  9. With the Cabinet

    Olivér Várhelyi

    Pharmaceutical package

    Published record
  10. With the Commissioner

    Michael McGrath

    Exchange of views on issues relating to competitiveness and corporate sustainability

    Published record

See all 17 meetings

Official entries

Checked against sources on 11 Nov 2026